Former British Army Chief Calls for Eased Restrictions on MDMA to Aid Veterans Suffering from PTSD.
Sir Nick Carter, a former head of the British military, is urging ministers to relax regulations surrounding the party drug MDMA in order to make it more accessible as a treatment option for veterans struggling with post-traumatic stress disorder (PTSD). The existing regulations pose a significant barrier to testing the efficacy of MDMA-assisted therapy, citing an inflated cost due to its classification as a class A drug.
Carter's plea comes on the heels of promising initial results from studies in Nature Medicine. In these trials, 71% of participants with PTSD showed significant improvement after undergoing MDMA-assisted therapy. This has sparked hopes that the treatment could be more effective than existing treatments for the condition, which affects approximately 9% of military veterans who served during deployments in Iraq and Afghanistan.
The benefits of MDMA-assisted therapy extend beyond the military community, with potential applications reaching workers in emergency services, healthcare professionals, and even police officers. According to Carter, this treatment could provide "a sense of self-love" and aid individuals in addressing chronic conditions like hyper-vigilance, flashbacks, and nightmares.
Martin Wade, a former lawyer who served in the British army, has been an outspoken advocate for PTSD support. Wade's experiences with the condition were exacerbated by his time in Afghanistan, where he struggled to cope with the moral implications of military operations. He has since become an artist and advocates for increased funding for therapy.
Critics argue that the government should provide more resources to address PTSD among veterans. Wade himself believes that providing each struggling veteran with ยฃ80,000 worth of therapy would be a valuable investment in their well-being. The Supporting Wounded Veterans charity is currently fundraising ยฃ2 million to support further trials of MDMA-assisted therapy at the University of Cambridge.
With promising results and mounting evidence supporting its efficacy, Carter's call for relaxed regulations on MDMA cannot be ignored. As the country grapples with the ongoing legacy of military operations, it remains to be seen whether increased access to this treatment option will have a lasting impact on veterans' lives.
Sir Nick Carter, a former head of the British military, is urging ministers to relax regulations surrounding the party drug MDMA in order to make it more accessible as a treatment option for veterans struggling with post-traumatic stress disorder (PTSD). The existing regulations pose a significant barrier to testing the efficacy of MDMA-assisted therapy, citing an inflated cost due to its classification as a class A drug.
Carter's plea comes on the heels of promising initial results from studies in Nature Medicine. In these trials, 71% of participants with PTSD showed significant improvement after undergoing MDMA-assisted therapy. This has sparked hopes that the treatment could be more effective than existing treatments for the condition, which affects approximately 9% of military veterans who served during deployments in Iraq and Afghanistan.
The benefits of MDMA-assisted therapy extend beyond the military community, with potential applications reaching workers in emergency services, healthcare professionals, and even police officers. According to Carter, this treatment could provide "a sense of self-love" and aid individuals in addressing chronic conditions like hyper-vigilance, flashbacks, and nightmares.
Martin Wade, a former lawyer who served in the British army, has been an outspoken advocate for PTSD support. Wade's experiences with the condition were exacerbated by his time in Afghanistan, where he struggled to cope with the moral implications of military operations. He has since become an artist and advocates for increased funding for therapy.
Critics argue that the government should provide more resources to address PTSD among veterans. Wade himself believes that providing each struggling veteran with ยฃ80,000 worth of therapy would be a valuable investment in their well-being. The Supporting Wounded Veterans charity is currently fundraising ยฃ2 million to support further trials of MDMA-assisted therapy at the University of Cambridge.
With promising results and mounting evidence supporting its efficacy, Carter's call for relaxed regulations on MDMA cannot be ignored. As the country grapples with the ongoing legacy of military operations, it remains to be seen whether increased access to this treatment option will have a lasting impact on veterans' lives.